Dow, Colorcon Add Excipients to Alliance Offerings
Dow and Colorcon extend and broaden the scope of the Controlled Release Alliance.
Colorcon and The Dow Chemical Company have agreed to broaden their existing Controlled Release Alliance to include Dow’s advanced technology-based pharmaceutical excipients, effective January 1, 2017. The Alliance, originally announced in July 2007, currently provides controlled-release technologies from Dow Pharma & Food Solutions, a business unit of Dow, to customers.
The Alliance offers provides customized solutions, products, and support services for pharmaceutical product development. The portfolio will include controlled-release technologies METHOCEL CR Cellulose Ethers, ETHOCEL polymers, and POLYOX resins; and excipient technologies including AFFINISOL polymers for solubility enhancement, ENTERACT polymers for enteric tablet coatings, and DUOLITE and AMBERLITE ion exchange resins for controlled release and other applications.
The addition of new technologies into the Alliance product portfolio expands the existing relationship between Colorcon and Dow and further enables formulation and development of fast-growing pharmaceutical applications, beyond the existing controlled release scope, the companies report in a press statement.
The agreement also renews an innovation partnership, in which Colorcon and Dow collaborate on the development and commercialization of controlled-release excipients.
Source: Colorcon and The Dow Chemical Company
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
